about
Structural basis for the differential classification of HLA-A*6802 and HLA-A*6801 into the A2 and A3 supertypesCross-Allele Cytotoxic T Lymphocyte Responses against 2009 Pandemic H1N1 Influenza A Virus among HLA-A24 and HLA-A3 Supertype-Positive IndividualsStructural basis of cross-allele presentation by HLA-A*0301 and HLA-A*1101 revealed by two HIV-derived peptide complexesStructural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy.Nosocomial Co-Transmission of Avian Influenza A(H7N9) and A(H1N1)pdm09 Viruses between 2 Patients with Hematologic Disorders.Cross-immunity Against Avian Influenza A(H7N9) Virus in the Healthy Population Is Affected by Antigenicity-Dependent Substitutions.Conserved epitopes dominate cross-CD8+ T-cell responses against influenza A H1N1 virus among Asian populations.The Serum Profile of Hypercytokinemia Factors Identified in H7N9-Infected Patients can Predict Fatal Outcomes.The first imported case of Rift Valley fever in China reveals a genetic reassortment of different viral lineagesAn unexpected N-terminal loop in PD-1 dominates binding by nivolumab.Revival of the identification of cytotoxic T-lymphocyte epitopes for immunological diagnosis, therapy and vaccine development.Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies.VP2 dominated CD4+ T cell responses against enterovirus 71 and cross-reactivity against coxsackievirus A16 and polioviruses in a healthy population.Hemagglutinin-specific CD4+ T-cell responses following 2009-pH1N1 inactivated split-vaccine inoculation in humans.Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients.An unexpected similarity between antibiotic-resistant NDM-1 and beta-lactamase II from Erythrobacter litoralisCorrigendum: The Serum Profile of Hypercytokinemia Factors Identified in H7N9-Infected Patients can Predict Fatal Outcomes.Two classes of protective antibodies against Pseudorabies virus variant glycoprotein B: Implications for vaccine design.CTL immunogenicity of Rv3615c antigen and diagnostic performances of an ESAT-6/CFP-10/Rv3615c antigen cocktail for Mycobacterium tuberculosis infection.Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab.Prolonged Evolution of Virus-Specific Memory T Cell Immunity after Severe Avian Influenza A (H7N9) Virus InfectionHeterosubtypic Protections against Human-Infecting Avian Influenza Viruses Correlate to Biased Cross-T-Cell ResponsesLimited Cross-Linking of 4-1BB by 4-1BB Ligand and the Agonist Monoclonal Antibody UtomilumabClinical, immunological and bacteriological characteristics of H7N9 patients nosocomially co-infected by Acinetobacter Baumannii: a case control studyGlycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapyReply to “Nuclear Export Signal and Immunodominant CD8 T Cell Epitope in Influenza A Virus Matrix Protein 1”Structural basis of HCoV-19 fusion core and an effective inhibition peptide against virus entry
P50
Q24338108-6FD379C2-5F36-416D-A288-0A1CF59E7FD7Q27673689-F2686D9A-0C49-4A77-893B-589915D90624Q27674409-3ACBFE3C-8BB6-4C12-B608-49E4A5125D7DQ29964482-4CE83E8B-5DFC-47AD-BFEC-530E504CD9ABQ30385714-4A66A057-2C7A-49F4-9A9A-B5F87494EA41Q30394072-E659C459-9542-4D2C-82DB-29A6125126C6Q30430651-F329D454-7F17-4E2E-9E9B-89EE1323995BQ30652541-AEC10B6C-1781-4845-B14F-DCC70EA7A693Q37617638-1D3E785D-4561-4472-8D79-A1BF1073EAABQ37637845-3B8593DD-3F85-47D1-B41E-DA3168FA94C8Q37844333-A2410FAE-C301-40CE-9C5A-BBDC608CD319Q38999322-F99AC1AB-CED2-4C8F-9382-D389D005F5A4Q39382773-A18F80B4-C9E8-470C-BCD6-408B9F8EEDF7Q41936253-D13B4BA3-38F7-4A0B-8C33-FF92EF1D3A8BQ42216434-6B318B7C-82F4-4281-BDC4-0C25A07B9C9AQ42566575-D95E4411-91ED-4F84-BDE8-DFF5F52DB146Q42585029-5A257F88-61B6-4C38-ACDC-FA4781F1DCBDQ47562844-5E25E67D-CBF9-43F2-A6BC-8A45027F6845Q47606855-EFEE32D7-DA8F-4498-AC1A-B9B950B7A3C6Q47783661-0FA3D38D-DBC7-436D-8827-BB5EB1D9A072Q56888955-D31B6CB2-3B42-4498-9442-7C9B984ABC54Q56975792-9D04F4D1-122C-4887-920E-5CFAD3428E21Q57796333-4BF31193-7377-4CAE-87B7-C24B77726238Q60044653-6239F761-8507-4B95-AC52-A2DEB41ABD21Q92497104-E93BDBFF-C6C9-4C0D-A7A2-824009058599Q93560734-6F93BFB5-77A3-4DBA-BC22-9BF5AFD60023Q96121100-7105E84B-88BF-456E-A22D-BEAB455FA03E
P50
description
researcher ORCID ID = 0000-0002-2599-4959
@en
wetenschapper
@nl
name
Shuguang Tan
@ast
Shuguang Tan
@en
Shuguang Tan
@es
Shuguang Tan
@nl
type
label
Shuguang Tan
@ast
Shuguang Tan
@en
Shuguang Tan
@es
Shuguang Tan
@nl
prefLabel
Shuguang Tan
@ast
Shuguang Tan
@en
Shuguang Tan
@es
Shuguang Tan
@nl
P1153
45961664600
P31
P496
0000-0002-2599-4959